Eric Karas - 02 Dec 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Reporting relationship: Chief Commercial Officer
Issuer ticker: SPRY
Reported as of: 02 Dec 2024
Net transaction value: -$125,423
SEC form: 4
Accepted by SEC: 04 Dec 2024, 21:40:04 UTC
Prior SEC filing: 19 Sep 2024
Next SEC filing: 03 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Kathleen Scott, Attorney-in-Fact

Key filing fact

Eric Karas filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 04 Dec 2024.

Key facts

This page summarizes Eric Karas's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Dec 2024, 21:40.

Change

Previous filing in this sequence was filed on 19 Sep 2024.
Current net transaction value: -$125,423.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPRY transaction

Common Stock

Options Exercise

Transaction value: $5,576
Shares: +3,717
Change %: +65%
Price: $1.50
Shares after: 9,410
Date: 02 Dec 2024
Ownership: Direct

SPRY transaction

Common Stock

Sale

Transaction value: $52,461
Shares: -3,717
Change %: -40%
Price: $14.11
Shares after: 5,693
Date: 02 Dec 2024
Ownership: Direct
Footnotes: F1, F2

SPRY transaction

Common Stock

Options Exercise

Transaction value: $9,424
Shares: +6,283
Change %: +110%
Price: $1.50
Shares after: 11,976
Date: 04 Dec 2024
Ownership: Direct

SPRY transaction

Common Stock

Sale

Transaction value: $87,962
Shares: -6,283
Change %: -52%
Price: $14.00
Shares after: 5,693
Date: 04 Dec 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRY transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -3,717
Change %: -0.63%
Price: $0.000000
Shares after: 590,871
Date: 02 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,717
Exercise price: $1.50
Footnotes: F3

SPRY transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -6,283
Change %: -1.1%
Price: $0.000000
Shares after: 584,588
Date: 04 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,283
Exercise price: $1.50
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.

Footnote F2

The weighted average sale price for the transaction reported was $14.1139, and the range of prices were between $14.00 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F3

Immediately exercisable.